Liminal BioSciences Inc. Common Shares
LMNL
LMNL was delisted on the 25th of September, 2023.
18 hedge funds and large institutions have $250K invested in Liminal BioSciences Inc. Common Shares in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
3,200% more call options, than puts
Call options by funds: $33K | Put options by funds: $1K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
38% less capital invested
Capital invested by funds: $405K → $250K (-$155K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$18.7K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11.2K |
| 3 |
Two Sigma Advisers
New York
|
+$10.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.37K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$86.4K |
| 2 |
Morgan Stanley
New York
|
-$41.6K |
| 3 |
VF
Virtu Financial
New York
|
-$20K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$562 |
LMNL Hedge Fund Activity: Q1 2022 in Review
18 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Liminal BioSciences Inc. Common Shares (LMNL) for Q1 2022, worth a combined $250K — down 38% from $405K a quarter earlier.
Fund positioning in LMNL was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was National Bank of Canada, adding an estimated $18.7K. The largest seller was Renaissance Technologies, cutting an estimated $86.4K.
- 18 institutional investors held Liminal BioSciences Inc. Common Shares (LMNL) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $250K of Liminal BioSciences Inc. Common Shares stock for Q1 2022, down 38% quarter-over-quarter.
- 2 funds opened new Liminal BioSciences Inc. Common Shares positions in Q1 2022 and 2 closed out, a net change of 0 holders.
- The largest Liminal BioSciences Inc. Common Shares buyer in Q1 2022 was National Bank of Canada, an estimated $18.7K added.
- The largest Liminal BioSciences Inc. Common Shares seller in Q1 2022 was Renaissance Technologies, an estimated $86.4K sold.
Based on aggregated 13F filings for Q1 2022.